Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1681 to 1695 of 8901 results

  1. Remdesivir for treating COVID-19 [ID3808]

    Awaiting development Reference number: GID-TA10721 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

    Awaiting development Reference number: GID-TA10723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]

    Awaiting development Reference number: GID-TA10909 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]

    Awaiting development Reference number: GID-TA10916 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]

    In development Reference number: GID-TA10966 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

    In development Reference number: GID-TA10998 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development Reference number: GID-TA11154 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]

    In development Reference number: GID-TA11160 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Renal cell carcinoma Pathways Pilot [ID6186]

    In development Reference number: GID-TA11186 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]

    Awaiting development Reference number: GID-TA11216 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]

    Awaiting development Reference number: GID-TA11218 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]

    Awaiting development Reference number: GID-TA11219 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]

    Awaiting development Reference number: GID-TA11469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]

    Awaiting development Reference number: GID-TA11700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]

    Awaiting development Reference number: GID-TA11673 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development